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FIGURE 3. Two stent profiles were seen on the long-axis view. Fully deployed stents had a biconic (left) or a conic (right) aspect. Note the waist zone (*) on
the left.
Brief Clinical Reportsindirect evidence of leaflet tissue to stent mismatch in at least
17.5% of cases. The clinical impact of these new data will
have to be determined.References
1. Vesely I. The evolution of bioprosthetic heart valve design and its impact on dura-
bility. Cardiovasc Pathol. 2003;12:277-86.From the Division of Cardiothoracic Surgery, Washington University School of
Medicine, Barnes–Jewish Hospital, St Louis, Mo.
Disclosures: None.
Received for publication Nov 7, 2009; revisions received Feb 24, 2010; accepted for
publication June 9, 2010.
Address for reprints: Rochus K. Voeller, MD, Department of Surgery, Washington
University School of Medicine, 660 South Euclid Ave, Box 8234, Saint Louis,
MO 63110 (E-mail: voellerr@wustl.edu).
J Thorac Cardiovasc Surg 2010;140:e56-8
0022-5223/$36.00
Copyright  2010 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2010.06.018
e56 The Journal of Thoracic and Cardiovascular Surg2. Christie GW. Computer modeling of bioprosthetic heart valves. Eur J Cardio-
thorac Surg. 1992;6(Suppl 1):S95-101.
3. Zegdi R, Ciobotaru V, Noghin M, Sleilaty G, Lafont A, Latremouille C, et al. Is
it reasonable to treat all calcified stenotic aortic valves with a valved stent? Re-
sults from a human anatomic study in adults. J Am Coll Cardiol. 2008;51:
579-84.
4. Litsler P-Y, Cribier A, Zajarias A, Comte D, Eltchaninoff H, Tron C, et al. Surgical
aortic valve replacement after percutaneous aortic valve implantation: what have
we learned? J Thorac Cardiovasc Surg. 2008;136:697-701.Novel use of plasmapheresis in a patient with heparin-induced
thrombocytopenia requiring urgent insertion of a left ventricular
assist device under cardiopulmonary bypassRochus K. Voeller, MD, Spencer J. Melby, MD, Brett E. Grizzell, MD, and Nader Moazami, MD,
St Louis, MoThe management of heparin-induced thrombocytopenia
(HIT) remains a major clinical challenge in adults requiring
cardiac surgery, especially when present preoperatively. Pa-
tients with end-stage heart failure are particularly vulnerable
to the development of HIT owing to their frequent and long-
term exposure to heparin. We report a case in which plasma-
pheresis was successfully used to eliminate the circulating
antiheparin platelet factor 4 (PF4) antibodies (Ab) to implant
a left ventricular assist device (LVAD) under cardiopulmo-nary bypass (CPB) with full heparinization, as routinely
performed.CLINICAL SUMMARY
The patient was a 47-year-old man with mild chronic
obstructive pulmonary disease and no significant medical his-
tory except for multiple recent hospitalizations for respiratory
decompensation, presumed to be secondary to exacerbation of
chronic obstructive pulmonary disease as well as pneumonia.
He was admitted to an outside institution with acute cardio-
genic shock, presumed to be secondary to acute viral myocar-
ditis, without any evidence of myocardial ischemia (negative
electrocardiographic findings, negative troponin levels). He
also had acute renal failure, hepatic ischemia with signifi-
cantly elevated transaminase levels, and rapid development
of respiratory failure necessitating emergency intubation. He
was started on inotropic support. An echocardiogram revealed
severe global biventricular hypokinesis with a left ventricular
ejection fraction of 7%, severe mitral and tricuspidery c September 2010
TABLE 1. Antiheparin platelet factor 4 antibody optical densities
Date Postop day Platelet count PF4 OD Comments
8/25/09 Preop 205 1.572
8/26/09 Preop 184 1.946
8/27/09 Preop 204 —
8/28/09 0 123 — ) CentriMag LVAD insertion without CPB or heparin
8/29/09 1 81 — Plasmapheresis day 1
8/30/09 2 86 — Plasmapheresis day 2
8/31/09 3 87 1.175 Plasmapheresis day 3
9/1/09 4 78 0.925 Plasmapheresis day 4
9/2/09 5 91 0.730 Plasmapheresis day 5
9/3/09 6 98 0.832 Plasmapheresis day 6
9/4/09 7 120 0.931 Plasmapheresis day 7
9/5/09 8 149 0.411 (negative)
9/6/09 9 148 —
9/7/09 10 172 0.511 (indeterminate)
9/8/09 11/1 187 0.463 ) HeartMate II device insertion on CPB with heparin
9/9/09 12/1 103 0.797
9/10/09 13/2 98 1.045
9/11/09 14/3 129 0.979
9/12/09 15/4 150 —
9/13/09 16/5 171 —
9/14/09 17/6 209 —
9/15/09 18/7 292 —
9/16/09 19/8 380 —
9/17/09 20/9 478 1.467
Antiheparin platelet factor 4 antibodies were considered negative if the optical density (OD) was less than 0.5. CPB, Cardiopulmonary bypass. CentriMag left ventricular assist
device, Levitronix, Waltham, Mass; HeartMate II device, Thoratec Corporation, Pleasanton, Calif.
Brief Clinical Reportsregurgitation, severe pulmonary hypertension, and a 23 1-cm
laminar left ventricular apical thrombus. Systemic hepariniza-
tion was immediately initiated. Cardiac catheterization re-
vealed no coronary artery disease. Two days after initiation
of the heparin drip, the patient becameprofoundly thrombocy-
topenic with a platelet count of 40,000/mL. Rapid-onset HIT
was subsequently diagnosed with a positive antiheparin PF4
Ab assay,whichwas confirmedby a positive serotonin release
assay. Heparin was immediately discontinued, and the patient
was started on a regimen of lepirudin.
The patient was extubated in approximately 1 week with
resolution of acute renal failure and liver injury, but he con-
tinued to receive high-dose inotropic support with minimal
improvement of the left ventricular ejection fraction for
3 weeks (10%–15% on follow-up echocardiograms). At
this time, the patient was transferred to our center for evalu-
ation of heart transplant versus LVAD placement. Soon after
his arrival, the hemodynamics deteriorated despite his
receiving 2 inotropic drugs and intra-aortic balloon pump
support, with a cardiac index of 0.8 L/m2. Repeat antiheparin
PF4 Ab and serotonin release assay were persistently posi-
tive on bivalirudin.
Inasmuch as the patient required urgent cardiovascular
support, the decision was made to place a temporary
LVAD (CentriMag; Levitronix, Waltham, Mass) off-pump
with inflow from the left atrium and outflow to the aorta.
The chest was closed. Bivalirudin was started 2 hours afterThe Journal of Thoracic and CaCentriMag LVAD insertion. Daily plasmapheresis was initi-
ated the following day for 7 consecutive days until the anti-
heparin PF4 Ab test results became negative (Table 1). He
was extubated and continued to receive bivalirudin during
this time. On postoperative day 8, the patient underwent ex-
plantation of the CentriMag LVAD, placement of a Heart-
Mate II device (Thoratec Corporation, Pleasanton, Calif),
and removal of the left ventricular apical thrombus under
CPBwith full heparinization and without any complications.
The patient did well postoperatively and was eventually dis-
charged to his home receiving warfarin sodium (Coumadin)
without any further complications of HIT.
DISCUSSION
HIT has become an enormous clinical entity in managing
patients undergoing cardiac surgery. HIT develops at a rate
of 1% to 3% postoperatively.1 When HIT is diagnosed
preoperatively in patients who need urgent or emergency
cardiac surgery that necessitates CPB, surgeons are faced
with a major dilemma: currently no consensus or data exist
to support the best strategy for anticoagulation for CPB
during the operation. Although alternative strategies for sys-
temic anticoagulation for CPB exist, they are all associated
with significant drawbacks.2
Owing to the urgent or emergency nature of this case,
waiting for antiheparin PF4 Ab negativity to place the
LVAD on CPB with heparin was not an option. We choserdiovascular Surgery c Volume 140, Number 3 e57
Brief Clinical Reportsnot to place the LVAD using bivalirudin or any other direct
thrombin inhibitors because this is associated with poten-
tially lethal bleeding complications.3 Some centers have re-
ported the use of unfractionated heparin and concomitant
potent platelet inhibitors for CPB in the setting of HIT. How-
ever, this approach has not been adopted at our institution.
The use of plasmapheresis for HIT is not a novel concep-
tion. Few studies have reported using plasma exchange
in the management of HIT with thrombosis.4 However, the
surgical literature contains only 1 case report in which
plasmapheresis was successfully used preoperatively in
a HIT-positive patient who required coronary artery bypass
grafting under CPB with heparin.5 To our knowledge, this is
the first reported case of plasmapheresis for a HIT-positive
patient requiring an LVAD.
This isolated experience suggests that plasmapheresis
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undergo cardiac surgery with CPB using systemic heparin-
ization. The more widespread use of this strategy should
be corroborated in a larger patient population.References
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lung transplantationTakahiro Oto,a Gregory I. Snell,b Keiji Goto,c and Shinichiro Miyoshi,a Okayama, Japan, and Melbourne,
AustraliaHemophagocytic syndrome (HPS) is a rare but occasionally
life-threatening complication after solid organ transplanta-
tion.1,2 This syndrome is characterized by phagocytizing
histiocytes that infiltrate tissues and phagocytize blood
elements and their precursors. The cause of this syndrome
is unknown.3 The development of HPS has been associated
with an uncontrolled excessive inflammatory response, and
the timely initiation of potentially life-saving therapy with
immunoglobulins and steroids is mandatory. Nonetheless,
the reported prognosis of this syndrome remains poor.1-3
There is no published information regarding HPS in lung
transplantation.We report a case of severe HPS related to Pseudomonas
infection in a lung transplant recipient.CLINICAL SUMMARY
A living-donor single lobar lung transplant was performed
for a patient with pulmonary veno-occlusive disease. The
primary immunosuppression consisted of 2 single doses of
basiliximab, daily doses of methylprednisolone, followed
by maintenance immunosuppression with tacrolimus (target
trough level: 10–15 ng/mL), mycophenolate mofetil, and
prednisolone. Results of blood tests for hepatitis C virus,
hepatitis B virus, cytomegalovirus, and Epstein–Barr virus
of the donor and the recipient were negative.
Pancytopenia (hemoglobin 8.3 g/dL, platelets 53 104/mL,
and neutrophils 0.6 3 103/mL) was first noted as a clinical
problem 8weeks after transplant (Figure 1). Low-grade fever
and mild splenomegaly were present. Elevated levels of
interleukin-2 receptor (2355 U/mL [normal range< 650]),
ferritin (6338 ng/mL [<138]), triglycerides (193 mg/dL
[<150]), aspartate aminotransferase (48 IU/L [<35]), alanine
aminotransferase (73 IU/L [<42]), alkaline phosphatase
(630 IU/L [<360]), g-glutanyl transferase (182 IU/L
[<40]), and fibrinogen (420 mg/dL [<390]) were also noted.
Bone marrow aspiration revealed massive hemophagocyticery c September 2010
